Protagenic’s PT00114 Breakthrough: New Hope for Stress Disorders

Protagenic Therapeutics Completes First Step of Phase I Clinical Trial for PT00114, a Promising Compound for Treating Stress-related Neuro-psychiatric Disorders

Protagenic Therapeutics, Inc. (PTIX), a prominent biopharmaceutical company, has successfully reached a significant milestone in its Phase I clinical trial for PT00114, a groundbreaking brain peptide compound aimed at addressing stress-related neuro-psychiatric disorders. The initial group of patients demonstrated excellent tolerance to a low dose of 125 micrograms, with no reported adverse reactions over a 30-day observation period.